Project Details
| Status | Finished |
|---|---|
| Effective start/end date | 04/7/16 → 04/6/19 |
Funding
- Boehringer Ingelheim Pharmaceutical: $89,973.82
A Phase III, randomised, double blind, placebo-controlled, parallel group, efficacy, safety and tolerability trial of once daily, oral doses of Empagliflozin as Adjunctive to inSulin
- Dandona, Paresh (PI)
- Ghanim, Husam (CoI)
- Makdissi, Antoine (CoI)
Project: Research